Abstract: The invention relates to disubstituted-aminodifluorosulfinium salts represented by the formula (I). Processes for preparing same and methods of use as deoxofluorinating reagent is also provided.

Abstract: The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process.

Abstract: The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process.

Abstract: The invention relates to disubstituted-aminodifluorosulfinium salts represented by the formula (I). Processes for preparing same and methods of use as deoxofluorinating reagent is also provided.

Abstract: The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1—R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Abstract: The instant invention provides novel processes and intermediates useful in the preparation of certain N-(indole-2-carbonyl)-&bgr;-alaninamide compounds, which compounds are glycogen phosphorylase inhibitors useful in the treatment of diseases such as hypercholesterolemia, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, diabetes, diabetic cardiomyopathy, infection, tissue ischemia, myocardial ischemia, and in inhibiting tumor growth.

Abstract: The instant invention provides novel processes and intermediates useful in the preparation of certain N-(indole-2-carbonyl)-&bgr;-alaninamide compounds, which compounds are glycogen phosphorylase inhibitors useful in the treatment of diseases such as hypercholesterolemia, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, diabetes, diabetic cardiomyopathy, infection, tissue ischemia, myocardial ischemia, and in inhibiting tumor growth.

Abstract: A process of preparing compounds having the formula I: or an optical isomer or racemic or optically active mixture thereof, which are useful as selective kappa-receptor agonists.

Abstract: A process of preparing compounds having the formula I: 1

Abstract: The recovery device includes a first tank containing a volume of water open in the inner space of the safety containment and a closed second tank isolated from the inner space of the safety containment. The second tank is smaller than the first tank, and is at least partly immersed in the water contained in the first tank. The inner volume of the immersed part of the second tank is placed in communication with the volume of water contained in the first tank by strainers. A discharge pipe is connected at one of its ends to a discharge point of the coolant circuit of the nuclear reactor and includes an end part opposite the discharge point opening into the interior of the second tank.

Abstract: A sheath for a nuclear reactor control rod consists of chromium nickel stainless steel. It is protected against friction wear by nitridation over a depth of from 15 to 50 .mu.m obtained by an electric discharge in a nitrogen containing atmosphere.

Abstract: Device for condensing steam under pressure consisting of a unit incorporating a storage vessel (6) containing cooling water, a distribution and heat exchange unit (15) fixed inside the storage vessel (6) and a water supply (30,31) for replacing the water in a storage tank (6) which is vaporized by contact with the tubes (24) of the distribution and heat exchange unit (15). A stack (7) is connected to the upper part of the storage vessel (6) and a tranquilizer grid is arranged in the storage vessel, above the heat exchange unit (15). The circulation of the fluid which is constituted of a two-phase mixture of water and steam is thus activated, while avoiding drawing out a significant quantity of water with the steam.

Abstract: Intrinsically safe emergency cooling device for a pressurized-water nuclear reactor, comprising an auxiliary circuit which feeds the steam generator and in which is arranged a condenser (10) receiving the steam from the generator and condensing it. The condensate is returned to the steam generator by means of gravity. The device also incorporates a passive adjustment means comprising an adjustable valve (21), a cylinder (23), the chamber of which communicates with the steam pipe (7) and contains a piston (33), and a coupling means (32) between the piston (33) and the shut-off element (30) of the valve (21). The feed rate of the steam generator and the cooling power of the condenser (10) can be regulated in this way.